Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL19236131 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL23134940 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL14380034 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502195-A | Methods of treating cancer using TNFRSF25 antibodies | 派立卡恩治疗公司 | 2022-05-13 | — | — | CN | claimed |
| CN-113747947-A | Combination therapy | 沙塔克实验室有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113382750-A | CDCP1 targeted therapy | 贝斯以色列女执事医疗中心 | 2021-09-10 | — | — | CN | claimed |
| CN-112203669-A | Microbiome-related immunotherapy | 克雷斯顿沃控股公司 | 2021-01-08 | — | — | CN | claimed |
| CN-105491999-A | Docetaxel polymeric nanoparticles for cancer treatment | BIND THERAPEUTICS INC | 2016-04-13 | — | — | CN | claimed |
| CN-103446040-A | Docetaxel-coated polymeric micelle and preparation method thereof | UNIV FUDAN | 2013-12-18 | — | — | CN | claimed |
| CN-100490850-C | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN NINGBO YINGNUO PHARMACE (CN) | 2009-05-27 | — | — | CN | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| US-20240197907-A1 | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240190967-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4380982-A1 | PROSTATE CANCER TREATMENT OR TREATMENT OF GYNECOLOGIC OR GENITOURINARY MALIGNANCY WITH A BISPECIFIC ANTIBODY THAT BINDS CTLA4 AND PD1 | Xencor, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4377320-A2 | ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. Scherer Technologies, LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-111511763-B | CD8 binding agents | 奥里尼斯生物科学有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2002038164-A1 | COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIFIER AND AN ANTICANCER AGENT AND USES THEREOF | LORUS THERAPEUTICS INC. (CA) | 2002-05-16 | — | — | WO | disclosed |
| WO-2000039590-A9 | PREDICTIVE METHODS BASED ON ALPHA-1-ACID GLYCOPROTEIN LEVELS | — | 2001-08-23 | — | — | WO | disclosed |
| US-6107497-A | Intermediate for use in docetaxel synthesis and production method therefor | NAPRO BIOTHERAPEUTICS, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000039590-A2 | PREDICTIVE METHODS BASED ON ALPHA-1-ACID GLYCOPROTEIN LEVELS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-5688977-A | Method for docetaxel synthesis | NAPRO BIOTHERAPEUTICS, INC. (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197907-A1 | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | ADAM8, BCR, JMJD7 | TUBB4A 2408/4885TUBB 1980/4885TUBA3C 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.